Long-term progression-free survival of a pre-treated patient with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil.

Trifluridine/tipiracil is approved for the use in later or last line setting in previously treated mCRC patients who progressed on standard anti-tumor drugs including 5-fluorouracil (5-FU), Irinotecan, Oxaliplatin, anti-VEGF- and anti-EGFR-antibodies or who are not considered candidates for those standard therapies. In this report, we describe a 67-year old male patient with KRAS-mutated mCRC and metachronous liver and lung metastasis who failed prior 5-fluorouracil- and irinotecan-containing regimens, but then showed long-term disease control for 31 months on single-agent trifluridine/tipiracil given as second-line treatment. According to our experience, trifluridine/tipiracil is a feasible and effective treatment option in earlier but not necessarily last line therapy in mCRC patients who are not considered candidates for doublet or triplet chemotherapy. Besides its efficacy, it is associated with maintained quality of life (QoL) and a manageable toxicity profile. Considering increasing age of mCRC patients and their wish for maintaining an independent life-style, further research on the use of trifluridine/tipiracil in earlier lines of systemic mCRC therapy is warranted.

Informations de copyright

S. Karger AG, Basel.